Experience That Can’t Be Replicated | Amgen Oncology Biosimilars

Oncology Biosimilars with Amgen— Your Complete Partner

We’ve invested ~ $2 billion in our biosimilars as part of our long-term commitment to help create a more economically sustainable healthcare system1

The Leading Oncology Biosimilars Portfolio That Continues To Grow

#1
prescribed trastuzumab
biosimilar2,*
#1
prescribed
bevacizumab3,
The Amgen
rituximab4

*Data collected from Q3 2019 to March 12, 2021. Data collected from April 24, 2020 to March 12, 2021.

Real-world evidence that can't be replicated5-10

Innovator Oncology PORTFOLIO

10

products, including therapeutic & supportive care

SUPPLY

0

SHORTAGES

including biosimilars, for more than a decade through natural disasters and during COVID-19

FAVORABLE
COVERAGE

>87%

of lives covered—unrestricted, with no step edit required for KANJINTI® and MVASI®§

Patients
Treated

>205k

with Amgen Biosimilars**

GLOBAL
Network

100

countries in the manufacturing & distribution network

Patients
SUPPORTED

4200+

by Amgen Assist 360 for MVASI® and KANJINTI®††

by Amgen Assist 360™
for MVASI® and
KANJINTI®††

  • From American Society of Health System Pharmacists: ongoing data monitoring (2007-2017) (2019-2021); FDA (2018-2020).
  • § From MMIT coverage in February 2021 for KANJINTI® and MVASI®. Covered is defined as covered with no step edit. The data represent plan participants enrolled in commercial and Medicare Advantage plans.
  • ** Based on global data, and includes an inflammation biosimilar.
  • †† As of March 2021.
callout-new-copy

At Amgen, we understand healthcare practice economics. That's why we're a proven long-term partner

See how your colleagues are experiencing
Amgen Oncology Biosimilars—watch the videos below

My Experience With Biosimilars

Lee Schwartzberg, MD, FACP
& Chris Marcum, PharmD

See their experiences with
Amgen biosimilars.

Choosing a Biosimilar Manufacturer

Lee Schwartzberg, MD, FACP
& Chris Marcum, PharmD

Understand why they consider
manufacturing quality to be important.

Institutional Adoption Process
for Biosimilars

Chris Marcum, PharmD

Hear his approach to successfully
adopting biosimilars.

Building Confidence in Extrapolation

Lee Schwartzberg, MD, FACP
& Chris Marcum, PharmD

Find out why they’re comfortable with
extrapolated indications.

Supply Shortages in Oncology

Chris Marcum, PharmD

Discover why reliable drug supply is critical in oncology.

Part 1: Are You Ready for Biosimilars? What the Oncology Team Should Know

Host, Matt Birnholz, MD
& Guest, Gary Cohen, MD

Learn about the development pathway
for biosimilars.

Part 2: Are You Ready for Biosimilars? What the Oncology Team Should Know

Host, Matt Birnholz, MD
& Guest, Gary Cohen, MD

Learn about the regulatory approval
pathway for biosimilars.

Heritage

"I was actually very excited [about Amgen Biosimilars] because Amgen has a very long experience in manufacturing biologics."

EXPERTISE

"I want a manufacturer who's got experience and has got enough scale to supply me with the product in an uninterrupted fashion. My patients deserve that and need that."

Dr Lee Schwartzberg, Oncologist

COMMITMENT

"When we choose a manufacturer, we look at product portfolio. If they are heavy in oncology and biologics, then we know that they know what they're doing."

SUPPORT

"Amgen does have a large support network and plenty of data available to help guide providers and pharmacists through some of these switches over from the reference product to a biosimilar."

Chris Marcum, Pharmacist
callout-hex-2

Learn more about the Amgen
Biosimilars development program

Pipeline of 3 biosimilars across therapeutic areas

Additional resources

download-1

Learn more about Amgen Biosimilars

References: 1. Data on file, Amgen [$2 Billion Invested]; 2019. 2. Data on file, Amgen [#1 Trastuzumab Biosimilar]; 2021. 3. Data on file, Amgen [#1 Bevacizumab]; 2021. 4. RIABNI™ (rituximab-arrx) Prescribing Information, Amgen. 5. Amgen Oncology. Products. www.amgenoncology.com. Accessed April 7, 2021. 6. Data on file, Amgen [Drug Shortages]; 2021. 7. Data on file, Amgen [Payer Coverage]; 2021. 8. Data on file, Amgen [Amgen Biosimilars Patients Worldwide]; 2021. 9. Amgen. About Amgen: Fact Sheet. www.amgen.com/~/media/amgen/full/www-amgen-com/downloads/fact-sheets/fact_sheet_amgen.ashx. Accessed April 7, 2021. 10. Data on file, Amgen [AA360]; 2021.